Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Annexon Inc (NQ: ANNX )

2.360 -0.050 (-2.07%)
Streaming Delayed Price Updated: 10:10 AM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,813
Open 2.340
Bid (Size) 2.360 (4)
Ask (Size) 2.370 (3)
Prev. Close 2.410
Today's Range 2.340 - 2.400
52wk Range 2.070 - 7.650
Shares Outstanding 47,722,995
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire

Performance

YTD
-50.73%
-50.73%
1 Month
-15.41%
-15.41%
3 Month
-29.45%
-29.45%
6 Month
-39.18%
-39.18%
1 Year
-60.86%
-60.86%

More News

Read More
The Latest Analyst Ratings for Annexon
Via Benzinga
Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results
From Annexon Biosciences
Via GlobeNewswire
Analyst Ratings for Annexon
Via Benzinga
Analyst Expectations for Annexon's Future
Via Benzinga
Why Annexon (ANNX) Stock Is Getting Hammered
Via Benzinga
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy
From Annexon Biosciences
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer
From Annexon Biosciences
Via GlobeNewswire
Annexon's Eye Disease Drug Reports Mixed Trial Results, Will Focus On Planned Late-Stage Study
Via Benzinga
Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023
From Annexon Biosciences
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 26, 2023
Via Benzinga
Crude Oil Drops Sharply; Best Buy Earnings Top Expectations
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Nasdaq Surges 1.5%; NVIDIA Shares Jump Following Strong Q1 Results
Via Benzinga
Why Shares of Annexon Are Plummeting Thursday
Via The Motley Fool
Why Dollar Tree Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2023
Via Benzinga
Dow Drops 100 Points; US GDP Tops Estimates
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function
From Annexon Biosciences
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback